In the described nonmycobacterial dermatologic context, which type of disease-modifying agent may be used?

In the described nonmycobacterial dermatologic context, which type of disease-modifying agent may be used?

• A. Corticosteroids
• B. Biologics
• C. csDMARDs
• D. Antibiotics

Answer: (C)

When managing chronic inflammatory skin diseases, the goal is to alter the disease course rather than just relieve symptoms. Conventional synthetic DMARDs are small-molecule medicines taken systemically that dampen immune activity and can slow or halt ongoing disease processes, making them appropriate as disease-modifying options in nonmycobacterial dermatologic contexts. These agents include drugs like methotrexate, azathioprine, mycophenolate, and leflunomide, which are used for long-term control of conditions such as psoriasis or autoimmune dermatitis. Corticosteroids mainly provide rapid, short-term relief of inflammation and are not considered long-term disease-modifying therapies. Biologics also modify disease activity but belong to a different category (biologic DMARDs) rather than conventional synthetic ones. Antibiotics target microbes or may have limited anti-inflammatory effects, but they do not change the underlying immune-driven disease process.

When managing chronic inflammatory skin diseases, the goal is to alter the disease course rather than just relieve symptoms. Conventional synthetic DMARDs are small-molecule medicines taken systemically that dampen immune activity and can slow or halt ongoing disease processes, making them appropriate as disease-modifying options in nonmycobacterial dermatologic contexts. These agents include drugs like methotrexate, azathioprine, mycophenolate, and leflunomide, which are used for long-term control of conditions such as psoriasis or autoimmune dermatitis. Corticosteroids mainly provide rapid, short-term relief of inflammation and are not considered long-term disease-modifying therapies. Biologics also modify disease activity but belong to a different category (biologic DMARDs) rather than conventional synthetic ones. Antibiotics target microbes or may have limited anti-inflammatory effects, but they do not change the underlying immune-driven disease process.